Attached files
| file | filename |
|---|---|
| EX-23.2 - EX-23.2 - PLUS THERAPEUTICS, INC. | cytx-ex232_652.htm |
| EX-32.1 - EX-32.1 - PLUS THERAPEUTICS, INC. | cytx-ex321_7.htm |
| EX-31.2 - EX-31.2 - PLUS THERAPEUTICS, INC. | cytx-ex312_6.htm |
| EX-31.1 - EX-31.1 - PLUS THERAPEUTICS, INC. | cytx-ex311_8.htm |
| EX-10.42 - EX-10.42 - PLUS THERAPEUTICS, INC. | cytx-ex1042_653.htm |
| EX-10.41 - EX-10.41 - PLUS THERAPEUTICS, INC. | cytx-ex1041_656.htm |
| EX-10.40 - EX-10.40 - PLUS THERAPEUTICS, INC. | cytx-ex1040_654.htm |
| EX-10.39 - EX-10.39 - PLUS THERAPEUTICS, INC. | cytx-ex1039_655.htm |
| EX-10.22 - EX-10.22 - PLUS THERAPEUTICS, INC. | cytx-ex1022_690.htm |
| EX-10.21 - EX-10.21 - PLUS THERAPEUTICS, INC. | cytx-ex1021_689.htm |
| 10-K - 10-K - PLUS THERAPEUTICS, INC. | cytx-10k_20161231.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Cytori Therapeutics, Inc.
San Diego, California
We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-215365), Form S-3 (Nos. 333-153233, 333-159912, 333-192409, 333-200090, and 333-195846) and Form S-8 (Nos. 333-210211, 333-202858, 333-181764, 333-82074, and 333-122691) of Cytori Therapeutics, Inc. (the “Company”) of our report dated March 24, 2017, relating to the 2016 consolidated financial statements and financial statement schedule, which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
/s/ BDO USA, LLP
San Diego, California
March 24, 2017